Portland, OR, United States
Portland, OR, United States
SEARCH FILTERS
Time filter
Source Type

An electronic construction collaboration system for managing a construction project is provided. The electronic construction collaboration system includes an Enterprise Resource Planning (ERP) sub-system including a contract engine configured to generate at least one project contract including a contract data set and ERP metadata corresponding to Building Information Modeling (BIM) metadata included in a structural object of a construction project model in a BIM sub-system and an interconnection engine configured to associatively link the ERP metadata and the BIM metadata and send the contract data set to the BIM sub-system in response to associatively linking the ERP metadata and the BIM metadata.


Sandy Thomas C.E.,Viewpoint
International Journal of Hydrogen Energy | Year: 2012

Battery electric vehicles (BEVs) and plug-in hybrid electric vehicles (PHEVs) are often labeled "green", implying that they will significantly reduce greenhouse gas (GHG) emissions. But actual GHG reductions will depend on two factors: the number of electric vehicles that can be sold to Americans that are fond of driving large vehicles long distances, and the GHGs emitted by the electrical power plants that charge the EV batteries. This article evaluates the maximum potential of EVs to cut GHG emissions and oil consumption in the U.S. and compares them with the GHG and oil reduction potential of hydrogen-powered fuel cell electric vehicles. Even if all US light duty vehicles (LDVs) (cars and trucks) were replaced by a combination of battery EVs for small vehicles and plug-in hybrids for all other LDVs, then GHGs could at most be reduced by 25% and oil consumption could be reduced by less than 67%. But if all LDVs in the U.S. were replaced by fuel cell electric vehicles powered by hydrogen made from natural gas, then GHGs would be immediately reduced by 44% and oil consumption by nearly 100%. © 2011, Hydrogen Energy Publications, LLC. Published by Elsevier Ltd. All rights.


A method for operating a building information modeling (BIM) system, is provided. The method includes at a BIM server, receiving a data alteration request from a client computing device for altering data in one of a building model, a hierarchical structure of building model data, and a Construction Operations Building Information Exchange (COBie) spreadsheet, the building model, hierarchical structure of building model data, and COBie spreadsheet simultaneously displayed in a GUI generated by the BIM server, automatically determining validity of data in the data alteration request, and if it is determined that the data is valid, permitting the data alteration request based on predetermined permissions of the client computing device.


A method for operating a BIM system is provided. The method includes at a BIM server, generating a network accessible graphical user interface (GUI) simultaneously displaying a 3-dimensional rendering of a building model, a hierarchical structure of building model data, and a Construction Operations Building Information Exchange (COBie) spreadsheet, the building model, hierarchical structure of building model data, and a COBie spreadsheet being associatively linked.


A method for operating a building information modeling (BIM) system is provided. The method includes at a BIM server, in response to receiving a save tri-dimensional data command from a client computing device, associatively mapping identification data in each of a building model, a hierarchical structure of building model data, and a Construction Operations Building Information Exchange (COBie) spreadsheet and storing a representation of the associative mapping of the identification data for display in at least one of the BIM server and a client computing device in electronic communication with the server over a network.


A method for operating a building information modeling (BIM) system, is provided. The method includes at a BIM server, receiving a data alteration request from a client computing device for altering data in one of a building model, a hierarchical structure of building model data, and a Construction Operations Building Information Exchange (COBie) spreadsheet, the building model, hierarchical structure of building model data, and COBie spreadsheet simultaneously displayed in a GUI generated by the BIM server, automatically determining validity of data in the data alteration request, and if it is determined that the data is valid, permitting the data alteration request based on predetermined permissions of the client computing device.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 149.84K | Year: 2015

DESCRIPTION provided by applicant Melanoma incidence is growing faster than any other cancer and the American Cancer Society reports that death rates for melanoma have been rising in the United States for the past years Alarmingly melanoma is the most common cancer in young adults under One characteristic of metastatic melanoma cells that is recognized as a potential target for new therapies is upregulation of cell surface melanocortin receptor subtype I MCR However there are no agents currently available that can be used to exploit this identifiable difference between melanoma cells and normal cells This proposal is focused on development validation and commercialization of novel class of theranostic Pb labeled peptides that bind with high affinity and specificity to MCR for targeted imaging and image guided therapy of metastatic melanoma Our innovative approach enlists matched pair isotopes Pb Pb to enable unambiguous dosimetry based on Pb SPECT imaging for Pb alpha particle therapy Viewpoint Molecular Targeting LLC has developed a strong business partnership with Radiomedix that is driving our development and commercialization of diagnostic SPECT radiotracer Pb DOTA VMT MCR which will be followed by radiotherapeutic agent Pb DOTA VMT MCR in future Randamp D Matched pair isotopes Pb Pb is also attractive due to a relatively long half life h of Pb which is favorable for centralized manufacturing of radiotracers for their direct shipment to imaging facilities and a h half life of Pb which can be commercialized through regional therapy centers Our overall objective is to develop effective theranostic approach for metastatic melanoma that improve diagnosis and therapy of melanoma and provide improved clinical outcomes with fewer milder side effects than current therapies To achieve these objectives we propose the following specific aims Scale up and perform IND enabling validation preparations of Pb DOTA VMT MCR for inclusion in an IND submission to the FDA for first in humans clinical imaging and Determine the feasibility of centralized manufacturing distribution of Pb DOTA VMT MCR for molecular imaging of metastatic melanoma Upon successful completion of our Aims we expect to have validated a manufacturing process for production of ultra high specific activity Pb DOTA VMT MCR and to have collected required CMC data for submission of our clinical imaging IND We further expect to have demonstrated the feasibility of centralized commercial manufacturing and distribution of Pb DOTA VMT MCR These successes are expected to advance VMT MCR through initial commercial risk mitigating milestones to a first in humans clinical trial with Pb DOTA VMT MCR for imaging melanoma of metastatic melanoma patients These studies are the foundation to advance our Pb DOTA VMT MCR therapy which has the potential to circumvent drug resistance that limits the effectiveness of current treatments for metastatic melanoma PUBLIC HEALTH RELEVANCE This proposal is aimed to establish the feasibility of a novel radiolabeled Pb labeled peptide conjugate for targeted imaging and future Pb based image guided therapy of metastatic melanoma No other agents are available that are based on this theranostic approach for metastatic melanoma cancer imaging and therapy


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 298.18K | Year: 2015

Not Available


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 298.53K | Year: 2016

DESCRIPTION provided by applicant Melanoma the fastest growing cancer incidence in the world today and the American Cancer Society reports that death rates for melanoma continue to rise Alarmingly melanoma is the most common cancer in young adults under One characteristic of metastatic melanoma cells that is recognized as a potential target for new therapies is upregulation of cell surface receptor melanocortin subtype I MCR However there are no agents currently available that exploit this identifiable difference between melanoma and normal cells This proposal is focused on development validation and commercialization of an automated system for the preparation of Pb labeled peptides that bind with high affinity and specificity to MCR for targeted imaging and therapy of metastatic melanoma Our innovative approach enlists matched pair isotopes Pb Pb to enable quantitative dosimetry based on Pb SPECT imaging for Pb alpha particle therapy Viewpoint Molecular Targeting LLC has developed a strong strategic business partnerships that are driving our commercialization of diagnostic therapeutic agents Pb DOTA VMT MCR Pb DOTA VMT MCR Matched pair isotopes Pb Pb is also attractive due to a relatively long half life h of Pb which is favorable for centralied manufacturing of radiotracers for their direct shipment to imaging facilities Our overall objectie is to develop effective image guided therapy for metastatic melanoma that will improve outcomes for melanoma patients with fewer milder side effects than current therapies To achieve these objectives we propose the following specific aims Determine the feasibility of an automated cassette based fluid handling system for clinical manufacturing of Pb labeled chelator modified VMT MCR and Determine the feasibility of Pb TCMC VMT MCR and Pb C N VMT MCR for molecular imaging and radionuclide therapy for metastatic melanoma With success in our Aims we expect to determine the feasibility of an automated system to produce high specific activity Pb VMT MCR under Aim We further expect to have determined the feasibility of three VMT MCR compositions to advance to clinical imaging trials via an eIND under Aim We expect these successes to have the positive impact of advancing VMT MCR through initial commercial risk mitigating milestones to a first in humans imaging trial with Pb VMT MCR We expect this to lead to Pb VMT MCR therapy which has the potential to circumvent drug resistance that limits the effectiveness of current treatments for metastatic melanoma PUBLIC HEALTH RELEVANCE This proposal is aimed to establish the feasibility of a novel automated system for the preparation of Pb and Pb labeled peptide conjugates for clinical imaging and image guided therapy of metastatic melanoma No other agents are available that are based on this approach for metastatic melanoma imaging and therapy


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 221.98K | Year: 2016

DESCRIPTION provided by applicant Cataracts affect an estimated million people in the United States annually and account for million cases of blindness worldwide Although surgical cataract extraction is a reliable procedure that substantially improves visual acuity in of cases it places a large financial burden on healthcare systems In the United States alone the annual direct cost of cataract treatment is over $ billion higher than the combined costs to treat glaucoma advanced macular degeneration and diabetic retinopathy Moreover in much of the developing world surgical intervention is simply not accessible for patients Cataracts are caused when accumulated damage to the major lens crystallin proteins including crystallin cryAB causes their unfolding and subsequent assembly into insoluble amyloids There are no approved therapies to cure or reverse cataracts Pharmacological chaperones are small molecules that bind and stabilize the native form of a protein Our research team in collaboration with chemist Dr Jason Gestwicki UCSF and ophthalmologist Dr Usha Andley Washington University recently developed a novel differential scanning fluorimetry DSF platform and identified molecules that stabilize the native fold of cryAB Employing a small molecule from this screen we were able to demonstrate prevention of the aggregation of cryAB and fully dis assembled pre formed aggregates in vitro and an ophthalmic solution of the andquot hitandquot molecule compound completely restored transparency to the eyes of a mouse model of severe cataract Remarkably this effect occurred after only weeks of topical treatment mirroring the reversal kinetics observed in vitro To further develop this discovery we will Aim Design and synthesize an initial focused library of pharmacological small molecule chaperones to destabilize crystallin amyloid Aim Screen and select small molecule chaperones in vitro by assessing efficacy and therapeutic index Iterate library as required Aim Screen and select compounds in vivo for efficacy in a murine age related cataract model as well as hereditary cataract model PUBLIC HEALTH RELEVANCE Cataract is the most common form of vision loss worldwide impacting the vision of million individuals in the US and andgt million worldwide In this proposal we will pursue a safe effective topical treatment for the reversal of cataracts

Loading Viewpoint collaborators
Loading Viewpoint collaborators